Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study Options for single-agent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback